BIOGEN IDEC al 64mo INCONTRO ANNUALE DELL'AMERICAN ACADEMY OF NEUROLOGY (AAN)Italia NewsL'espansione di cellule Natural Killer CD56bright predice la risposta al trattamento con daclizumab HYP in casi di sclerosi multipla recidivante-remittente …
Nuevos datos presentados en el 64º Congreso Anual AAN destacan el compromiso …elEconomista.es… de investigación de su cartera en última fase, incluido: BG-12, interferón beta-1a PEGylado, y el proceso de alto rendimiento de daclizumab (DAC HYP)…
Haga doble click sobre una palabra para ver su signifcadoelEconomista.es… de investigación de su cartera en última fase, incluido: BG-12, interferón beta-1a PEGylado, y el proceso de alto rendimiento de daclizumab (DAC HYP) para EM; y dexpramipexo…
Biogen Idec to present new neurology data at AAN 2012 meetingZenopaNew data will highlight the safety and efficacy of the marketed products Tysabri, Avonex and Fampyra, as well as results from investigational trials of key late-stage compounds such as …
Partager BFM surBFM Business… de son pipeline de molécules en phase finale, dont : BG-12, interféron bêta-1a pégylé et DAC HYP (procédé à haut rendement du daclizumab) pour la SEP ; et dexpramipexole, un traitement potentiel pour la sclérose…
Biogen Idec presenteert nieuwe data op American Academy of Neurology …Nieuws.nlDaarnaast presenteert Biogen Idec de resultaten van onderzoeksproeven zoals de BG-12, PEGylated interferon beta-1a, en daclizumab high-yield process (DAC HYP) voor multipl…
Biogen Idec assume un ruolo significativo durante l'importante congresso di …ANSA.it… sua pipeline per terapie nelle fasi finali, fra cui: BG-12, interferone pegilato beta-1a e il processo daclizumab ad alto rendimento (DAC HYP) per la SM; oltr…
Auf der 64. AAN-Jahrestagung präsentierte Daten unterstreichen das Engagement …Live-PR.com (Pressemitteilung)… PEGyliertes Interferon Beta-1a und Daclizumab High-Yield Process (DAC HYP) für MS sowie Dexpramipexol, eine potenzielle Therapie für a…
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's …EON: Enhanced Online News (press release)… and FAMPYRA ® (prolonged-release fampridine tablets) – the company will present results from investigational trials of its lat…
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's …Financial Post… and FAMPYRA ® (prolonged-release fampridine tablets) – the company will present results from investigational trials of its late-stage pipeline, including…